Mold-Tek Packaging Limited (NSE: MOLDTKPAC), India\u2019s pioneer in In-Mold Labeling (IML), announced its Q3 FY26 financial results today. The company reported a mixed set of numbers, characterized by steady year-on-year revenue growth and a breakout performance in its nascent Pharma division, even as sequential profitability faced headwinds due to higher depreciation and finance costs associated with recent capacity expansions.<\/p>\n\n\n\n
Metric<\/strong><\/td>| Q3 FY26 (\u20b9 Cr)<\/strong><\/td> | Q3 FY25 (\u20b9 Cr)<\/strong><\/td> | YoY Change (%)<\/strong><\/td> | QoQ Change (%)<\/strong><\/td><\/tr><\/thead> | Revenue<\/strong><\/td> | 198.44<\/td> | 190.69<\/td> | +4.1%<\/td> | -3.8%<\/td><\/tr> | EBITDA<\/strong><\/td> | 19.09<\/td> | 18.18<\/td> | +5.0%<\/td> | -2.7%<\/td><\/tr> | Net Profit (PAT)<\/strong><\/td> | 14.35<\/td> | 13.64<\/td> | +5.2%<\/td> | -14.6%<\/td><\/tr> | EPS<\/strong><\/td> | \u20b94.11<\/td> | \u20b94.27<\/td> | -3.8%<\/td> | –<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n | Segment Performance: The Pharma Catalyst<\/h2>\n\n\n\nThe highlight of the quarter was undeniably the Pharma Packaging Division, which has transitioned from an investment drag to a growth engine in record time.<\/p>\n\n\n\n Pharma Ramp-up: Revenue from the Pharma segment jumped to \u20b92.27 crore in Q3, up from just \u20b91 crore in Q2. Management noted that the run-rate accelerated significantly in January 2026 alone, crossing \u20b92.1 crore for the month.<\/p>\n\n\n\n Capacity Expansion: The division is currently operating at 40-45% capacity utilization. To meet surging demand, Mold-Tek is importing advanced Italian machinery, scheduled for installation by mid-February, which will further bolster capacity for high-margin, tamper-evident caps and closures.<\/p>\n\n\n\n New Wins: The company secured approvals for new molds and has begun commercial supplies to key clients, including Biocon Pharma.<\/p>\n\n\n\n Strategic Partnerships & Future Roadmap<\/h2>\n\n\n\nVibe Generation (UK) Partnership: Signed a Memorandum of Understanding (MoU) to manufacture precision caps and closures. This deal is estimated to have a revenue potential of $25-30 million (\u20b9210-250 Cr) over the next five years, opening doors to high-value export markets.<\/p>\n\n\n\n Swiggy Alliance: Entered an MoU with Swiggy to provide sustainable packaging solutions for its vast network of restaurant partners, signaling a strong entry into the “Quick Commerce” packaging ecosystem.<\/p>\n\n\n\n Consolidation: The company is consolidating its manufacturing operations in Hyderabad to optimize logistics and overheads, with efficiency benefits expected to kick in from Q1 FY27.<\/p>\n\n\n\n Management Commentary<\/h2>\n\n\n\nMr. J. Lakshmana Rao, CMD, addressed the sequential margin compression, attributing it to the “gestation costs” of their aggressive expansion.<\/p>\n\n\n\n “We are witnessing a structural shift in our revenue mix. The Pharma division has turned profitable in less than 12 months, a testament to our execution capabilities. While interest and depreciation costs are currently weighing on net margins, the volume traction in F&F (Food & FMCG) and the high-value Pharma orders give us confidence for a strong FY27.”<\/p>\n\n\n\n He also clarified that the recent Income Tax demand notice of \u20b94.83 crore is being contested and is not expected to have any material financial impact on operations.<\/p>\n\n\n\n Investor Outlook & Conclusion<\/h2>\n\n\n\nThe stock closed at \u20b9545.50, reflecting a muted reaction as the market digests the sequential profit decline.<\/p>\n\n\n\n Investors are betting on the “Pharma + Exports” thesis. If the Pharma division achieves its projected \u20b950-55 crore revenue target for next fiscal, it could trigger a significant re-rating of the stock.<\/p>\n\n\n\n The “Paints” segment remains vulnerable to raw material volatility and sluggish rural demand.<\/p>\n\n\n\n The near-term weakness is viewed as a consolidation phase. Long-term investors are watching the execution of the Panipat and Cheyyar plants, which are critical for reducing logistics costs and serving major clients like Asian Paints and Castrol more efficiently.<\/p>\n","protected":false},"excerpt":{"rendered":" Mold-Tek Packaging Limited (NSE: MOLDTKPAC), India\u2019s pioneer in In-Mold Labeling (IML), announced its Q3 FY26 financial results today. The company reported a mixed set of numbers, characterized by steady year-on-year revenue growth and a breakout performance in its nascent Pharma division, even as sequential profitability faced headwinds due to higher depreciation and finance costs associated […]<\/p>\n","protected":false},"author":2383,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,9825,392,5],"tags":[8196],"class_list":["post-180161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings-call-highlights","category-earnings","category-latest","tag-packaging"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":179344,"url":"https:\/\/alphastreet.com\/india\/mankind-pharma-q3-fy26-earnings-results\/","url_meta":{"origin":180161,"position":0},"title":"Mankind Pharma Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"February 3, 2026","format":false,"excerpt":"Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. Q3 FY26 Earnings Results Revenue from Operations: \u20b93,567 cr, +11.5% YoY (vs \u20b93,200+ cr last year) driven by strong domestic chronic portfolio demand. EBITDA: \u20b9925 cr\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-36.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":179627,"url":"https:\/\/alphastreet.com\/india\/xpro-india-q3-fy26-earnings-results\/","url_meta":{"origin":180161,"position":1},"title":"XPRO India Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"February 5, 2026","format":false,"excerpt":"XPRO India Ltd is engaged mainly in the business of polymers processing at multiple locations and is a leading manufacturer in India of Coextruded Plastic Films, thermoformed liners and specialty films (including dielectric films and special purpose BOPP Films). Q3 FY26 Earnings Results Revenue from Operations: \u20b9106.31 cr, +1.7% YoY\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":173228,"url":"https:\/\/alphastreet.com\/india\/srf-q3-fy26-earnings-results\/","url_meta":{"origin":180161,"position":2},"title":"SRF Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 21, 2026","format":false,"excerpt":"Incorporated in 1970, SRF Ltd manufactures and sells technical textiles, chemicals, packaging films, aluminum foils, and other polymers. Q3 FY26 Earnings Results Gross Operating Revenue: \u20b93,712.5 crore, up 6.3% YoY from \u20b93,491.3 crore in Q3 FY25; up 1.99% QoQ from ~\u20b93,640 crore in Q2 FY26. Revenue from Operations: \u20b93,712.53 crore,\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"SRF Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":179008,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-q3-fy26-earnings-results\/","url_meta":{"origin":180161,"position":3},"title":"Sun Pharmaceutical Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"February 2, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/image-17.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":179802,"url":"https:\/\/alphastreet.com\/india\/shree-renuka-sugars-q3-fy26-earnings-results\/","url_meta":{"origin":180161,"position":4},"title":"Shree Renuka Sugars Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"February 6, 2026","format":false,"excerpt":"Incorporated in 1995, Shree Renuka Sugars Ltd does manufacturing and refining of sugar, ethyl alcohol, ethanol, generation and sale of power. Q3 FY26 Earnings Results Revenue from Operations: \u20b92,273 cr consolidated, -12.7% YoY (vs \u20b92,603 cr in Q3 FY25), and -6.2% QoQ (from \u20b92,423 cr in Q2 FY26). EBITDA \/\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":178100,"url":"https:\/\/alphastreet.com\/india\/rpg-life-sciences-q3-fy26-earnings-results\/","url_meta":{"origin":180161,"position":5},"title":"RPG Life Sciences Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 28, 2026","format":false,"excerpt":"Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients. Q3 FY26 Earnings Results Revenue from Operations: \u20b9180.03 cr, +4.24% YoY vs \u20b9172.71 cr, \u22120.91% QoQ vs \u20b9181.68 cr. EBITDA: \u20b939.76 cr (PBDIT excl OI), +2% QoQ, margin 22.09% (+61 bps QoQ).\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-96.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2383"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180161"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180161\/revisions"}],"predecessor-version":[{"id":180163,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180161\/revisions\/180163"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} |